SCHEMBL1931173

SCHEMBL1931173

COc1cc(C(=O)c2nc(NS(C)(=O)=O)c3ccccn23)ccc1[N+](=O)[O-]

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ LMNA P02545 3/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ MEN1 O00255 4/20 0.37
▸ HPGD P15428 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ GAA P10253 2/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MAPT P10636 5/20 0.36
▸ CFTR P13569 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ ABCB1 P08183 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1931390 0.89 ALDH1A1 (0.40) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1930678 0.87 ALDH1A1 (0.40) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1931650 0.84 ALDH1A1 (0.38) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1931663 0.83 MAPK1 (0.43) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1931559 0.83 ALDH1A1 (0.40) ALDH1A1KMT2ALMNAMAPK1MEN1
Hydrochloric Acid SCHEMBL1931669 0.82 MAPK1 (0.42) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1931410 0.82 ALDH1A1 (0.42) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1930915 0.80 ALDH1A1 (0.41) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL3597150 0.80 ALDH1A1 (0.51) ALDH1A1KMT2ALMNAMAPK1MEN1
SCHEMBL1930756 0.79 RORC (0.45) ALDH1A1KMT2ALMNAMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633216-B2 Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI (FR) 2014-01-21 — — US disclosed
EP-1861403-B1 NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SA (FR) 2012-05-02 — — EP disclosed
US-8008321-B2 Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications SANOFI-AVENTIS (FR) 2011-08-30 — — US disclosed
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2011-06-09 — — US disclosed
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-05-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same CYP3A5, CYP4B1, CYP3A7 ALDH1A1 238/4885KMT2A 2940/4885LMNA 3137/4885
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same P2RX6, IL5, ATIC ALDH1A1 711/4885KMT2A 3462/4885LMNA 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback